Want to see GCTK full AI Analyst Report?
Top Page
GlucoTrack
(NASDAQ:GCTK)
Select Model
Select Model
Rating:42Neutral
Price Target:
$3.00
▲(782.35% Upside)
Action:Reiterated
Date:09/06/26
The score is primarily constrained by weak financial performance (no revenue, large and persistent losses, and accelerating cash burn with negative equity in TTM). Technicals also remain unfavorable with the stock trading far below major moving averages and bearish momentum. Corporate events provide some offset via new funding and development progress, but dilution and early-stage execution risk remain key.
Positive Factors
Low Debt Burden
Minimal absolute debt reduces near-term debt-servicing pressure and leaves fewer fixed claims on operating resources. If the company eventually commercializes its technology, a low debt load could provide greater flexibility than a heavily leveraged balance sheet.
Negative Factors
No Commercial Revenue
The absence of reported revenue shows that the company has not yet demonstrated commercial traction or a proven monetization engine. Persistent losses while pursuing development increase dependence on future financing and make durable profitability contingent on successful commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Debt Burden
Minimal absolute debt reduces near-term debt-servicing pressure and leaves fewer fixed claims on operating resources. If the company eventually commercializes its technology, a low debt load could provide greater flexibility than a heavily leveraged balance sheet.
Read all positive factors
GlucoTrack (GCTK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.38M
Dividend YieldN/A
Average Volume (3M)1.16M
Price to Earnings (P/E)―
Beta (1Y)2.24
Revenue GrowthN/A
EPS Growth99.51%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-180.45
Shares Outstanding798,144
10 Day Avg. Volume76,856
30 Day Avg. Volume1,163,216
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GlucoTrack Business Overview & Revenue Model
Company Description
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glu...
How the Company Makes Money
null...
GlucoTrack Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
34
Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -43.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -16.02M | -19.35M | -21.93M | -7.08M | -4.41M | -3.94M |
| Net Income | -15.95M | -19.39M | -22.60M | -7.10M | -4.43M | -4.07M |
Balance Sheet | ||||||
| Total Assets | 1.50M | 7.84M | 5.93M | 4.91M | 2.44M | 6.26M |
| Cash, Cash Equivalents and Short-Term Investments | 1.12M | 7.38M | 5.62M | 4.49M | 2.31M | 6.06M |
| Total Debt | 19.00K | 33.00K | 267.00K | 196.00K | 195.00K | 250.00K |
| Total Liabilities | 3.24M | 5.01M | 18.93M | 1.71M | 1.21M | 1.11M |
| Stockholders Equity | -1.74M | 2.83M | -13.00M | 3.20M | 1.23M | 5.16M |
Cash Flow | ||||||
| Free Cash Flow | -16.31M | -15.34M | -12.59M | -6.56M | -3.73M | -3.77M |
| Operating Cash Flow | -16.22M | -15.24M | -12.49M | -6.56M | -3.73M | -3.77M |
| Investing Cash Flow | -87.00K | -96.00K | -104.00K | 0.00 | 1.00K | -1.00K |
| Financing Cash Flow | 7.88M | 17.04M | 13.74M | 8.73M | 0.00 | 0.00 |
GlucoTrack Technical Analysis
Negative
0.34
Price Trends
5.59
Negative
7.46
Negative
25.61
Negative
Market Momentum
-0.74
Positive
32.98
Neutral
1.60
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GCTK, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 4.77, below the 50-day MA of 5.59, and below the 200-day MA of 25.61, indicating a bearish trend. The MACD of -0.74 indicates Positive momentum. The RSI at 32.98 is Neutral, neither overbought nor oversold. The STOCH value of 1.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GCTK.
GlucoTrack Risk Analysis
GlucoTrack disclosed 57 risk factors in its most recent earnings report. GlucoTrack reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GlucoTrack Peers Comparison
UnderperformOutperform
Sector (51)
GCTK
GlucoTrack
2.98
-68.12
-95.81%
FEMY
Femasys
2.98
-4.72
-61.29%
WOK
WORK Medical Technology Group LTD
2.10
-782,497.90
-100.00%
GlucoTrack Corporate Events
Shareholder MeetingsStock Split
GlucoTrack Executes Reverse Stock Split to Restructure Shares
Neutral
Aug 28, 2026
GlucoTrack implemented a one-for-15 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on Aug. 28, 2026, following shareholder approval at its Aug. 18, 2026 annual meeting. The move consolidated every 15 issued and outsta...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
GlucoTrack Announces 1-for-15 Reverse Stock Split
Neutral
Aug 27, 2026
On August 27, 2026, Glucotrack, Inc. announced it would implement a 1-for-15 reverse stock split of its common stock, effective at the opening of trading on August 31, 2026, with the shares continuing to trade on Nasdaq under the symbol GCTK. The ...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
GlucoTrack Shareholders Approve Key Governance and Capital Actions
Positive
Aug 19, 2026
On August 18, 2026, Glucotrack, Inc. held its annual meeting of stockholders, where shareholders elected six directors to serve until the 2027 meeting and approved, on an advisory basis, the 2025 executive compensation of the company’s named...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
GlucoTrack Amends Equity Financing and Issues Commitment Shares
Neutral
Aug 10, 2026
On August 7, 2026, Glucotrack, Inc. amended its July 14, 2026 common stock purchase agreement with White Lion Capital, LLC, revising the terms under which the investor receives 2,505,513 commitment shares of common stock tied to a $1,000,000 fee a...
Business Operations and StrategyPrivate Placements and Financing
GlucoTrack Secures New Financing to Support Growth
Positive
Aug 5, 2026
On August 4, 2026, Glucotrack entered into definitive agreements for approximately $5.5 million in follow-on and interim financing with institutional investors, combining a $3.5 million senior secured convertible bridge investment and a $2.0 milli...
Business Operations and StrategyProduct-Related Announcements
GlucoTrack Advances LT-100 to Single-Injection Development Strategy
Positive
Jul 30, 2026
On July 29, 2026, Lōkahi Therapeutics, a wholly owned subsidiary of Glucotrack, announced progress in the development strategy for LT-100, a therapeutic candidate whose historical administration required up to 15 intradermal injections per tr...
Business Operations and StrategyPrivate Placements and Financing
GlucoTrack Restructures Debt Through Equity-Linked Note Exchange
Neutral
Jul 27, 2026
On July 22, 2026, Glucotrack, Inc. entered into a new Exchange Agreement with an existing investor to restructure part of a promissory note originally issued on September 12, 2025, and subsequently reduced through prior exchange agreements in Apri...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.